Loading patent…
AssigneesTakeda Vaccines, Inc., The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
InventorsDan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
Estimating the term…
Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
An immunogenic composition comprising a modified live, attenuated dengue-2 virus strain PDK-53, the immunogenic composition being a tetravalent composition, wherein the modified live, attenuated dengue-2 virus strain PDK-53
Dependencies are inferred from the claim text.